Background and Rationale for Revised Clinical and Laboratory Standards Institute Interpretive Criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam
Background and Rationale for Revised Clinical and Laboratory Standards Institute Interpretive Criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam
复制标题
DOI：
10.1093/cid/cit017
复制
发表时间：
2013-05-01
影响因子：
11.8
通讯作者：
Jones, Ronald N.
中科院分区：
文献类型：
--
作者：
Dudley, Michael N.;Ambrose, Paul G.;Jones, Ronald N.
由于超广谱β-内酰胺酶(ESBL S)，肠杆菌科细菌和铜绿假单胞菌对头孢菌素和单菌素类抗生素产生了广泛的耐药性，需要重新评估20多年前为这些药物建立的解释标准(断点)。经过广泛的评估，临床和实验室标准研究所最近通过并公布了这些药物在临床实验室中使用的新断点，并提供了使用ESBL筛查测试的最新建议。本文综述了头孢菌素类和氨曲南检测肠杆菌科细菌的新的解释标准的背景和支持的理由。
Widespread resistance in Enterobacteriaceae and Pseudomonas aeruginosa to cephalosporin and monobactam antibiotics due to extended-spectrum beta-lactamases (ESBLs) has resulted in the need for reassessment of the interpretative criteria (breakpoints) established for these agents more than 2 decades ago. Following extensive evaluation, the Clinical and Laboratory Standards Institute recently adopted and published new breakpoints for these agents for use in clinical laboratories and provided updated recommendations for use of the ESBL screening test. This paper summarizes the background and supportive rationale for new interpretative criteria for cephalosporins and aztreonam for testing Enterobacteriaceae.